Purpose Depression and anxiety are highly comorbid psychiatric conditions and both are common in adult patients with migraine. This study aims to examine the unique associations between major depressive disorder (MDD) and generalized anxiety disorder (GAD) in a well-characterized group of older adolescents and college-age individuals with migraine. Method Participants (N = 227), between 15 and 20 years old, who were unmedicated or within 1 month of beginning antidepressant treatment underwent a comprehensive psychiatric assessment to establish the presence of MDD and GAD, according to the Diagnostic and Statistical Manual, Fourth Edition, Text Revision, and to rate their symptom severity using the Longitudinal Interval Follow-up Evaluation for Adolescents (A-LIFE). They then completed the IDMigraine. The Student's t test and chi-square test were used to compare continuous and categorical variables, respectively, across participants with vs. without migraine. Logistic regression analysis examined the association between the presence of migraine and psychopathology. Results A diagnosis of MDD was associated with significantly increased risk of having migraine. Moreover, more severe and persistent ratings of depression were associated with an even higher likelihood of having migraine. A diagnosis of GAD was also significantly associated with the presence of migraine. The prevalence of comorbid MDD and GAD was significantly higher in participants with migraine than those without migraine (55 vs. 22%, p < 0.0001). When examined concurrently, GAD remained significantly associated with migraine, with a statistical trend for MDD to be associated with it. Conclusion The comorbidity of migraine, MDD, and GAD has important clinical and research implications. Patients who suffer from any of these problems should be screened for all three in order to receive comprehensive care. Shared psychological and biological vulnerabilities may be involved in the three conditions. Greater understanding of the shared vulnerabilities can lead to unified treatments.
Introduction
Internalizing disorders, which include depressive and anxiety disorders, are prevalent. In fact, major depressive disorder (MDD) is a leading cause of disability worldwide and is associated with suicide, substance use disorders, and social and educational impairment [1, 2] . In adolescents, the 1-year prevalence of MDD is 4 to 5%; and its lifetime prevalence is upward of 11% [2, 3] . Anxiety disorders, including generalized anxiety disorder (GAD), are similarly common in adolescents, with a prevalence ranging between 10 and 20% [1] . Notably, anxiety disorders are often comorbid with MDD among youth [1] .
Like internalizing disorders, migraine is a chronic condition that significantly impacts quality of life and functioning, including academic performance in adolescents and college students [4] . The prevalence of migraine differs by age and sex [5] . Among females, it increases from 7.0% before the age of 14 years to 9.7% by age 20. In contrast, boys 14 years old and younger have a prevalence of 4.7%, increasing to 6.0% by age 20.
Importantly, MDD, GAD, and migraine are often comorbid. In fact, adults with migraine have twice the prevalence of MDD of non-migraineurs [6, 7] . Moreover, migraine comorbid with MDD is more chronic, disabling, and treatment resistant than migraine without MDD [6] . In children, the findings regarding the association between MDD and migraine are less consistent, with some studies reporting no association and others finding higher severity of depressive symptoms or a prevalence of MDD as high as 9.5% in those with migraine or chronic daily headaches [6, [8] [9] [10] [11] . As for comorbid anxiety disorders, they predict persistence of migraine and headache-related disability [12] . Notably, this association appears to be bidirectional, as migraineurs have higher prevalence of anxiety disorders [6] . In contrast to children and adults, less is known about the association between MDD, GAD, and migraine in older adolescents and college-age individuals [12] . Some studies, combining children and adolescents, have shown an association [8, 13, 14] , while others fail to do so [15, 16] .
We used a psychiatrically well-characterized sample of older adolescents and college-age individuals [17] [18] [19] to (1) examine the association between MDD and migraine, (2) examine the association between GAD and migraine, and (3) to disentangle the independent roles of MDD versus GAD in migraine. To our knowledge, this is the first study that aims to disentangle the independent roles of depression versus anxiety in adolescents and young adults with migraine. Gaining a better understanding of which psychiatric symptoms are prevalent and problematic for migraine can lead to more focused screenings and interventions for patients.
Methods
This analysis draws on data from an observational parent study aimed at examining the skeletal effects of selective serotonin reuptake inhibitors (SSRIs) [17] [18] [19] . Participants (N = 227) were 15 to 20 years old, recruited from inpatient and outpatient clinical settings, via word of mouth and by advertisement. Study participation was restricted to individuals who were not taking psychotropics or who were within 1 month of starting an SSRI. Approximately half of the participants enrolled in the study were within a month of starting an SSRI. The use of psychotropics within 2 years prior to enrollment led to exclusion, with the exception of benzodiazepines (n = 3), trazodone (n = 1), α2 agonists (n = 1), or a stable dose of psychostimulants (n = 2). Other exclusionary criteria included the presence of eating disorders, substance-use disorders, pregnancy, a significant medical or surgical history, or plans to move out of state in the following year. The University of Iowa Institutional Review Board approved the study, and all adult participants or parents/guardians of minor participants provided written informed consent. The minors also gave written assent and consent.
Procedures: Participants presented for a baseline intake visit, followed by monthly phone contacts. Every 4 months, they returned for an in-person, follow-up visit for a total study participation of 2 years. Psychiatric diagnoses based on the Diagnostic and Statistical Manual of Mental Disorders IV Text Revision (DSM-IV-TR) [1] 1 incorporated information from an unstructured interview conducted by a child psychiatrist (CAC), the National Institute of Mental Health Diagnostic Interview Schedule for Children (DISK-IV) [20] , and the review of medical records and the self-and researcher-completed symptom rating scales. As detailed elsewhere [17] , MDD and GAD severity was quantified for each week throughout the study, starting at 4 months prior to enrollment, using the Longitudinal Interval Follow-up Evaluation, modified for use with adolescents (A-LIFE) [21] . The A-LIFE psychiatric status rating (PSR) scores range from 1 for no symptoms to 2 to 4 for varying levels of symptom severity and impairment and to 5 and 6 for full DSM-IV-TR criteria. This allowed generating the proportion of weeks during the observation period, starting 4 months prior to study entry, in which MDD or GAD ratings indicated that diagnostic criteria had been met.
The ID Migraine was also completed by the participants [22] . The three-item ID Migraine questionnaire is widely used to screen for migraine headaches in primary care settings. It has a specificity of the screener not impacted by age or sex [22] . The ID Migraine has been validated in adolescents aged 12-17 [23] . Other studies have validated it in university students aged 17 and older (mean ages 19 to 21) [24, 25] . In addition, demographic, socioeconomic, substance-use, and other self-reported data of psychiatric symptoms were collected.
Statistical Analyses
Patients who endorsed at least two of the three items in the ID Migraine screener (n = 31, 14%) comprised the positivemigraine group [23] . The positive-and negative-migraine groups were compared, using Student's t test for continuous variables and chi-square or Fisher's exact for categorical ones. While adjusting for relevant confounding variables, 2 we examined the association between the presence of migraine and psychopathology, using logistic regression analysis. The adjusted odds ratios (ORs) with their 95% confidence intervals (CIs) were computed. Body mass index (BMI) was computed as weight/height 2 (kg/m 2 ), and BMI age-sex-specific Z-scores were generated, based on the 2000 Centers for Disease Control and Prevention normative data [26] . All hypothesis tests were two-tailed, with a significance level of p < 0.05, and analyses used procedures from SAS version 9.3 for Windows (SAS Institute Inc., Cary, NC). Table 1 lists the demographic and clinical characteristics of the sample overall and split, based on whether participants had a positive migraine screen. As expected, the positive-migraine group included more females.
Results

Migraine and Depression
After adjusting for female sex (OR = 2.6, 95% CI = 1.0, 6.6, p = 0.047), having a diagnosis of MDD was associated with a higher prevalence of migraine (OR = 3.4, 95% CI = 1.1, 10.2, p = 0.029). Age did not significantly contribute to the model (OR = 1.1, 95% CI = 0.8, 1.4, p = 0.6676).
In order to rule out SSRI treatment as a confounding factor, we repeated the analysis after excluding participants who stopped (n = 26) or started (n = 2) SSRI treatment between study entry and administration of the ID Migraine screener. The association remained significant (OR = 4.9, 95% CI = 1.4, 17.0, p = 0.0127). Adjusting, instead, for SSRI treatment (OR = 2.2, 95% CI = 0.8, 5.6, p = 0.1122) also did not alter the magnitude of the association (OR = 3.3, 95% CI = 0.9, 3.0, p = 0.0842).
When the A-LIFE-based proportion of weeks meeting DMS-IV-TR criteria for a major depressive episode (MDE) was substituted for the diagnosis of MDD, the association with migraine became stronger (OR = 5.2, 95% CI = 1.8, 14.8, p = 0.0021). In other words, after adjusting for sex (OR = 2.5, 95% CI = 1.0, 6.4, p = 0.0660), we found that patients who were in a major depressive episode during the entire observational period had five times higher chances of also having migraine. Again, restricting the analysis to those whose SSRI treatment status did not change between study entry and administration of the ID Migraine screener did not alter the results (OR = 6.0, 95% CI = 2.0, 18.2, p < 0.002) nor did adjusting for SSRI treatment status (OR = 4.1, 95% CI = 1.1, 15.2, p < 0.04), which itself failed to significantly contribute to the model (OR = 1.8, 95% CI = 0.6, 4.9, p = 0.2625).
Effect of GAD
After adjusting for sex (OR = 2.5, 95% CI = 1.0, 6.5, p = 0.0565), having a diagnosis of GAD was significantly associated with the presence of migraine (OR = 3.0, 95% CI = 1.3, 6.8, p = 0.0101). Again, age was not a significant covariate (OR = 0.9, 95% CI = 0.7, 1.2, p = 0.6767).
Twenty-six percent of the participants had comorbid MDD and GAD. The prevalence of comorbidity was significantly higher in participants with migraine (55 vs. 22%, p < 0.0001). To examine the independent contribution of MDD and GAD to the risk of having migraine, both were concurrently entered in the logistic regression model. After adjusting for sex (OR = 2.3, 95% CI = 0.9, 6.0, p = 0.0869), we found that GAD remained significantly associated with migraine (OR = 2.4, 95% CI = 1.1, 5.3, p = 0.0366), with a statistical trend for MDD to be associated with it (OR = 2.7, 95% CI = 0.9, 8.4, p = 0.0786). When the sample was restricted to those whose SSRI treatment status did not change between study entry and administration of the ID Migraine screener, and after sex (OR = 2.6, 95% CI = 0.9, 7.5, p = 0.0816) and SSRI treatment status (taking an SSRI OR = 1.9, 95% CI = 0.7, 5.1, p = 0.1761) were adjusted for, the association between MDD and GAD, on the one hand, and migraine, on the other, failed to reach significance, although the ORs did not significantly change (OR of having MDD = 3.0, 95% CI = 0.8, 11.7, p = 0.1093 and OR of having GAD = 1.7, 95% CI = 0.7, 4.2, p > 0.2366). This suggests that the sample size may have limited the study's statistical power. Of note, model diagnostics to examine possible effects of collinearity for MDD and GAD were reviewed and did not reveal a concerning pattern.
The A-LIFE-based proportion of weeks meeting GAD criteria was also associated with migraine (OR = 6.2, 95% CI = 2.1, 18.4, p = 0.0011). When the sample was restricted to those whose SSRI treatment status did not change, and sex (OR = 2.6, 95% CI = 0.9, 7.4, p = 0.0813) and SSRI treatment status (OR = 1.3, 95% CI = 0.5, 3.7, p = 0.5882) were adjusted for, proportion of weeks meeting GAD criteria remained significantly associated with migraine (OR = 4.7, 95% CI = 1.1, 19.6, p = 0.0329) but not proportion of weeks meeting MDE criteria (OR = 2.1, 95% CI = 0.5, 8.7, p = 0.3158).
Discussion
Depression and anxiety are highly comorbid psychiatric problems, and both are common among adult patients with migraine. Our results extend findings in children and adults to older adolescents and college-age individuals, confirming that the presence of migraine is associated with a higher prevalence of MDD and GAD. The association was more consistent with GAD and was observed whether DSM-IV-TR-based diagnoses or A-LIFE-based symptom severity were used.
In this study, a diagnosis of MDD was associated with a 3.4-fold increase in the risk of having migraine. Furthermore, more severe and persistent MDD ratings were associated with an even higher likelihood of having migraine. This difference likely reflects the fact that the DSM-IV-TR-based MDD diagnosis does not capture the varying severity levels (i.e., ranging from full remission to severe with psychosis) and duration of MDD, which the A-LIFE was designed to do. This would also be consistent with the fact that adjusting for SSRI treatment, which is a marker of symptom severity (i.e., more severe symptoms will more likely lead to initiating treatment), somewhat attenuated the OR. The comorbidity of migraine and MDD is thought to reflect some common etiopathological pathways related to psychosocial stress, poor lifestyle habits, avoidance behavior, and biological mechanisms, as well.
GAD is often comorbid with MDD and was also strongly associated with migraine. Therefore, we sought to disentangle these associations and, indeed, found that taking GAD into account attenuates the association between MDD and migraine. To our knowledge, the independent association between MDD and GAD, on the one hand, and migraine, on the other, has not been examined in this age group. The finding that GAD is more strongly associated with migraine than MDD is consistent with other studies showing that pain conditions are more strongly related to anxiety disorders than to MDD [27] .
SSRIs in general are not considered an effective group of migraine-preventive drugs. However, there is some evidence suggesting that venlafaxine may be effective in migraine prevention [28] [29] [30] . Furthermore, certain SSRIs have also been associated with headaches as a side effect [31, 32] . Thus, to minimize any potential confounding effects of SSRIs in this (89) 12 (5) 10 (4) 2 (1) 25 (81) 2 (6) 3 (10) 1 (3) 178 (91) 10 (5) 7 (4) 1 (1) 0 Generalized anxiety disorder, n (%) 72 (32) 17 (55) 55 ( (48) 86 (38) 22 (71) 18 (58) 88 (45) 68 (35) 0.007
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BMI body mass index, MDD major depressive disorder, MDE major depressive episode, GAD generalized anxiety disorder, SSRIs selective serotonin reuptake inhibitors study, we (1) restricted the sample to participants whose SSRI status did not change between study entry and administration of the ID migraine and (2) adjusted for SSRI treatment. These additional analyses continued to reveal a 3-to 4-fold increase in the risk of having migraine in the presence of MDD. It is possible that SSRIs resulted in improved migraine severity. This would attenuate the associations we found. It is also unlikely that the participants' reported headaches were exacerbated by SSRIs because the ID migraine was administered more 4 four months after study entry.
One of the main strengths of this study is that the diagnoses of MDD and GAD were made by a child psychiatrist, based on a variety of information, including an unstructured and a structured interview. This differentiates it from many other studies which used only rating scales, with limited sensitivity and specificity. In patients with migraine specifically, the shortcomings of rating scales are exacerbated by the overlap in several symptoms (e.g., nausea, headache, or fatigue) between migraine and MDD or GAD [33] . Additionally, participants were followed prospectively, increasing the accuracy of the psychiatric diagnoses.
There are important clinical implications regarding the associations between migraine, MDD, and GAD. First, this comorbidity is associated with increased risk for suicidality, medication overuse, and disability [4, 34, 35] . Second, prospective studies indicate the presence of a bidirectional relationship between internalizing disorders on the one hand and migraine on the other, with each disorder increasing the risk for the onset of the other [36, 37] . Thus, screening adolescents and young adults who suffer from migraine for both anxiety and depression, and vice versa, could result in improved treatment options and improved long-term outcomes for the patient. Further, integrated treatments that target shared underlying vulnerabilities may be valuable.
Mechanisms underlying the comorbidity between internalizing disorders and migraine have focused on neurochemical processes [38] . More recently, however, attention has been placed on shared psychological vulnerabilities between pain conditions and psychopathology [39] . For example, patients with migraine exhibit more avoidance behaviors than do healthy controls and those with lower levels of acceptance report more pain-related interference and disengagement from activities [40] . Similarly, patients with MDD and/or GAD exhibit more avoidance behaviors, and lower levels of acceptance, than do their non-depressed/anxious counterparts [41] . Thus, integrated psychosocial interventions that focus on reducing avoidance, increasing engagement, and improving acceptance may help with the migraine pain, MDD, and GAD [42] [43] [44] . Thus, in light of their prevalence, finding treatments that help target both migraine and comorbid MDD/GAD will have significant public health implications.
Although this study offers novel findings, particularly related to the independent association between MDD and GAD with migraine, it suffers from several shortcoming. First, the ID Migraine was used to screen for migraine. This screener tool has been validated and has high sensitivity and specificity [22] . However, it does not distinguish between episodic and chronic migraine and may underestimate the prevalence of episodic migraine (i.e., subjects that have not had a migraine attack in more than 3 months). Additionally, it fails to assess the severity of migraine symptoms. Clearly, a clinician-based diagnosis of migraine, along with assessment of migrainerelated disability, would have been optimal. Second, a few psychotropic groups were allowed at study entry. Some of these medications may lead to headaches. However, only a few participants took them, rendering their potential effect on the findings negligible. Third, this study was launched before the DSM-5 became available. However, changes made to the diagnostic criteria of MDD and GAD sections were minimal and are unlikely to alter our findings. Finally, this sample was mainly a Caucasian population including many college students, with half having started an SSRI. The general population is more diverse, less educated, and most will go untreated for their psychiatric difficulties. Our results will likely generalize to a population of higher-functioning students who attend high school and college and have access to care.
In conclusion, in a group of older adolescents and collegeage individuals, migraine was associated with both GAD and MDD, although to a stronger degree with the former. The use of SSRIs did not appear to significantly alter these findings. The psychological [42] and biological processes that underlie the association between migraine and internalizing disorders deserve further investigation as do interventions to alleviate the increased suffering that marks this comorbidity.
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